Eicosapentaenoic Acid Modulation of Membrane Lipid Packing and Oxidation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiovascular diseases are inadequate in addressing membrane cholesterol domain formation and oxidative modification of polyunsaturated fatty acids, leading to unresolved cardiovascular issues.

Innovation Solution

Administration of eicosapentaenoic acid or its derivatives to reduce or prevent membrane cholesterol domain formation and oxidative modification, thereby addressing cardiovascular-related diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current cardiovascular treatments are used, then some cardiovascular issues can be managed, but membrane cholesterol domain formation and oxidative modification of polyunsaturated fatty acids remain unresolved

Engineering Contradiction:

Improveeffectiveness of cardiovascular treatmentVSAvoidmembrane cholesterol domain formation and oxidative modification

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using eicosapentaenoic acid (EPA), which has antioxidant properties, to convert the harmful oxidative modification process into a beneficial protective mechanism. EPA donates electrons to stabilize polyunsaturated fatty acids against oxidation, thereby transforming the harmful oxidative stress into a protected state that prevents cholesterol domain formation and reduces cardiovascular risk.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If eicosapentaenoic acid is administered, then membrane cholesterol domain formation is reduced, but the mechanism requires understanding of lipid metabolism complexity

Engineering Contradiction:

Improvemembrane cholesterol domain formationVSAvoidlipid metabolism mechanism complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies this principle by introducing eicosapentaenoic acid as an intermediary substance that mediates between oxidative stress and membrane stability. EPA acts as an electron donor that stabilizes polyunsaturated fatty acids, preventing the formation of cholesterol domains without requiring direct manipulation of the complex lipid metabolism pathways. This intermediary approach simplifies the overall mechanism while achieving the desired protective effect.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If eicosapentaenoic acid is administered, then oxidative modification of membrane polyunsaturated fatty acids is prevented, but the pharmaceutical composition requires precise formulation

Engineering Contradiction:

Improveoxidative modification of membrane polyunsaturated fatty acidsVSAvoidpharmaceutical composition formulation

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent applies this principle by focusing on the chemical properties and concentration parameters of eicosapentaenoic acid in the pharmaceutical composition. By optimizing the EPA concentration and formulation parameters, the patent achieves effective prevention of oxidative modification while maintaining manufacturability. The approach involves adjusting dosage parameters and composition ratios to balance therapeutic efficacy with manufacturing feasibility.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Eicosapentaenoic acid effectively reduces membrane cholesterol domain formation and oxidative modification, improving lipid profiles and reducing cardiovascular disease risk factors.

Implementation Method 1

EPA is a potent electron donor that stabilizes membrane polyunsaturated fatty acids against oxidation

Methodology Applied

Scientific EffectElectron donation:

Implementation Method 2

EPA disrupts the packing of membrane lipids and inhibits the formation of cholesterol domains

Methodology Applied

Scientific EffectLipid packing modulation:

Data Source

PatentUS11446269B2Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids

Publication Date: 2022.09.20 AMARIN PHARMACEUTICALS IRELAND LIMITED(IE)

AI summary

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL (“sdLDL”) oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.